Clinical Advisory Board |
|
|
Timotheus L.Th.A. Jansen, MD PhD | Rheumatology
Timotheus (Tim) Jansen, MD, PhD, joined Olatec’s Drug Development Team in February 2016 and became a Chairman of the Clinical Advisory Board in February 2019. Dr. Jansen has been contributing leading expertise in the design and conduct of Olatec’s human clinical trials in gout, including serving as Principal Investigator in the first and second clinical trial with dapansutrile for acute gout flares. He has over 20 years of clinical experience in both academic positions and private practice in rheumatology focused on gouty arthritis. Dr. Jansen is currently the Head of the Department of Rheumatology at VieCuri Medisch Centrum/Northern Limburg, Venlo, the Netherlands. From 2006-2012, Dr. Jansen was a Board member of the Dutch Society of Rheumatology and presided on its Quality Committee and he coauthored “Consumer Quality index in RA”, the national guideline: “Diagnosis and treatment of RA”, the national set of “quality indicators of RA”, and the national guideline: “Appropriate use of Biologicals in rheumatic diseases”. In addition, he has published over 200 PubMed publications covering cardiovascular and rheumatology topics. He is a member of the editorial board of Clinical Rheumatology and reviewer for several Rheumatology journals. Dr. Jansen was trained in Internal Medicine and Rheumatology at Academic Hospital St. Radboud, Nijmegen, the Netherlands and Rijnstate Hospital, Arnhem, the Netherlands, where he received his PhD in April 1993. Jose Ángel Cordova Villalobos, MD| Clinical Design
Dr. Córdova served as Mexico’s Federal Health Secretary from 2006-2011 and as Federal Secretary of Education in 2012 in President Felipe Calderon’s Administration, in addition to holding other senior-level public health offices in his country. He is board certified in General Surgery, Digestive Surgery and Gastrointestinal Endoscopy and belongs to the National Academies of Medicine and Surgery of Mexico, and the National Academies of Medicine and Surgery of France, in addition to several other medical societies. Dr. Córdova has also held numerous academic positions including the President of Mexico’s National Association of Faculty and Schools of Medicine. Dr. Córdova has published over 80 articles or scientific papers in national and international medical journals, 20 medical books chapters and was editor of four medical books. He has also participated and presented in over 250 national or international health forums. Dr. Córdova was decorated as a Chevalier of the French Légion d’honneur and has received over 40 prestigious awards for his service and commitment to the betterment of the healthcare in Mexico and internationally. Dr. Córdova graduated from León ́s Faculty of Medicine, specializing in Internal Medicine at the National Institute of Medical Sciences and Nutrition “Salvador Zubirán”, and studied General Surgery and Digestive Endoscopy at the Paul Sabatier University in Toulouse. He has a master’s degree in Public Administration from the Faculty of Law of the University of Guanajuato and has received the Honoris Causa Doctorate from four universities including the Paul Sabatier University in Toulouse. Marc Donath, MD, PhD| Endocrinology, Diabetes and Metabolism
Dr. Donath, a renowned immuno-endocrinologist, has been recently appointed as Medical Director of the Diabetes Centre at the University Hospital Montreal, Canada and is former Chief Physician in Endocrinology, Diabetes and Metabolism at the University of Basel, Switzerland. Dr. Donath is globally recognized for his pioneering contributions to immunometabolism, particularly his discovery of the inflammatory process underlying type 2 diabetes (T2D). In addition, he has made numerous contributions to the concept that the innate immune system is an integral component in the regulation of metabolism, also known as immunometabolism. He showed that metabolic stress induces an IL-1β mediated immune response. He confirmed this hypothesis in the first clinical study showing that modulation of the immune system may improve metabolism and cardiovascular diseases in patients with type 2 diabetes. Matthijs Janssen, MD, PhD| Rheumatology
Matthijs Janssen, MD, PhD, joined Olatec’s Drug Development Team in February 2016 and became a member of the Clinical Advisory Board in October 2019. In collaboration with Dr. Tim Jansen, Dr. Matthijs Janssen has been contributing leading expertise in all areas of Olatec’s clinical program in gout, including serving as Investigator in the first and second clinical trials with dapansutrile for acute gout flares. Dr. Janssen has over 30 years of experience in rheumatological disease and specializes in treatment modalities and co-morbidities of gout, research in gastro- intestinal damage resulting from use of NSAIDs, and clinical trials in gout and reactive arthritis. Dr. Janssen is currently a rheumatologist at VieCuri Medisch Centrum/Northern Limburg, Venlo, the Netherlands. From 1992 – 2017, Dr. Janssen was a rheumatologist at Rijnstate Hospital in Arnhem, the Netherlands, where he trained approximately 40 rheumatologists. Dr. Janssen chairs the creation of the Dutch Guidelines on gout disease. He has authored publications on gout in The Lancet, Archives of Internal Medicine and in the Annals of Rheumatic Diseases and (co-) authored more than 120 national and international PubMed publications. Dr. Janssen also serves as a reviewer of many Rheumatology Journals. Dr. Janssen studied at the University of Groningen, the Netherlands and was trained in Internal Medicine (Medical Spectrum Twente; Enschede) and Rheumatology (Leiden University Medical Centre; Leiden). He received his PhD in May 1994. |